You are here: Industry Insights > antibody

News List

ProBioGen Announces Innovent as a New Partner Signing License of GlymaxX® Technology B3Cnewswire
January 14, 2022
ProBioGen today announced that Innovent Biologics, Inc. (1801.HK) has signed a multi-product license for ProBioGen's GlymaxX technology.
ABL Bio and Sanofi partner to develop antibody for Parkinson’s disease Pharmaceutical-Technology
January 13, 2022
ABL Bio will receive $985m in milestone payments from Sanofi in addition to royalties on the net sales of the product.
Twist-Revelar’s therapy neutralises Omicron and Delta variants Pharmaceutical-Technology
January 07, 2022
Twist Bioscience and Revelar Biotherapeutics have reported data from live virus studies where their therapy, RBT-0813, showed it binds to and neutralises SARS-CoV-2 Omicron and Delta variants.
BiondVax Announces Successful Closing of $9.8 million Follow-on Underwritten Offering of ADSs Including Exercise of the Over-Allotment FirstWordPharma
December 30, 2021
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses...
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors prnasia
December 28, 2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the Center for Drug Evaluation...
Valneva Announces Positive Booster Data for COVID Vax Candidate contractpharma
December 17, 2021
Valneva SE announced positive homologous booster data from the Phase 1/2 study, of its inactivated, adjuvanted COVID-19 Vaccine candidate, VLA2001.
Evusheld Long-Acting Antibody Combination Retains Neutralizing Activity Against Omicron Variant in Independent FDA Study AmericanPharmaceuticalReview
December 17, 2021
AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data.
New Treatment Greatly Boosts Survival for Kids With Aggressive Brain Cancer Drugs
December 13, 2021
Children with the rare cancer neuroblastoma often succumb to the disease despite aggressive treatment. But researchers have found that adding an experimental antibody to that treatment, right off the bat, may improve their outlook.
New Asthma Drug, Dupilumab (Dupixent) Helps Kids, But Price Tag Is High Drugs
December 10, 2021
Children with hard-to-control asthma may get relief from adding an injectable antibody drug to their standard treatment, a clinical trial has found.
FDA OKs Antibody Cocktail to Help Immune-Compromised Fend Off COVID Drugs
December 10, 2021
The U.S. Food and Drug Administration on Wednesday granted emergency approval of a new antibody cocktail to prevent COVID infection in people who have weakened immune systems or who can't tolerate COVID vaccines.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page